Remix Therapeutics is a biotechnology company focusing on modulating RNA processing through small molecule therapies to address the underlying causes of disease, according to a Jan. 5 release from the company.
Dr. Bowden previously served as the chief medical officer and a strategy adviser for Agios from 2014 to 2022. He also spent eight years at Genentech, where he was the vice president of product development oncology.
Dr. Bowden also has experience as the executive director of the Europe, Middle East and Africa regions for New York-based pharmaceutical company Bristol-Myers Squibb.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.